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Abstract
Background: A single non-invasive gene expression profiling (GEP) test (AlloMap®) is often used to discriminate if
a heart transplant recipient is at a low risk of acute cellular rejection at time of testing. In a randomized trial, use
of the test (a GEP score from 0–40) has been shown to be non-inferior to a routine endomyocardial biopsy for
surveillance after heart transplantation in selected low-risk patients with respect to clinical outcomes. Recently,
it was suggested that the within-patient variability of consecutive GEP scores may be used to independently
predict future clinical events; however, future studies were recommended. Here we performed an analysis of an
independent patient population to determine the prognostic utility of within-patient variability of GEP scores in
predicting future clinical events.
Methods: We defined the GEP score variability as the standard deviation of four GEP scores collected ≥315 days
post-transplantation. Of the 737 patients from the Cardiac Allograft Rejection Gene Expression Observational
(CARGO) II trial, 36 were assigned to the composite event group (death, re-transplantation or graft failure
≥315 days post-transplantation and within 3 years of the final GEP test) and 55 were assigned to the control
group (non-event patients). In this case-controlled study, the performance of GEP score variability to predict
future events was evaluated by the area under the receiver operator characteristics curve (AUC ROC). The
negative predictive values (NPV) and positive predictive values (PPV) including 95 % confidence intervals (CI)
of GEP score variability were calculated.
Results: The estimated prevalence of events was 17 %. Events occurred at a median of 391 (inter-quartile range
376) days after the final GEP test. The GEP variability AUC ROC for the prediction of a composite event was 0.72
(95 % CI 0.6-0.8). The NPV for GEP score variability of 0.6 was 97 % (95 % CI 91.4-100.0); the PPV for GEP score
variability of 1.5 was 35.4 % (95 % CI 13.5-75.8).
Conclusion: In heart transplant recipients, a GEP score variability may be used to predict the probability that a
composite event will occur within 3 years after the last GEP score.
Trial registration: Clinicaltrials.gov identifier NCT00761787
Keywords: Heart transplant, Gene expression profiling, AlloMap, Surveillance of cardiac recipients, Acute cellular
rejection, AlloMap score variability, Gene expression profiling score
* Correspondence: johan.vanhaecke@uzleuven.be
15University Hospital of Leuven, Leuven, Belgium
16Department of Cardiology, Herestraat 49, 3000 Leuven, Belgium
Full list of author information is available at the end of the article
© 2015 Crespo-Leiro et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Crespo-Leiro et al. BMC Cardiovascular Disorders  (2015) 15:120 
DOI 10.1186/s12872-015-0106-1
Background
In a landmark article published more than 40 years ago,
Dr. Philip Caves and colleagues described the percutan-
eous transvenous endomyocardial biopsy (EMB) and re-
ported their experience with the 67 cardiac biopsies
performed in 17 cardiac transplant recipients [1]. Since
then, serial EMB has become the standard of care for
monitoring transplant rejection status in adult patients
[2]. Despite its wide acceptance, EMB has several limita-
tions. First, patients who undergo EMB, particularly those
undergoing biopsy surveillance for a prolonged period of
time, are at increased risk of complications [3]. Second,
the pathological interpretation can be subjective [4, 5].
Third, the procedure can only detect rejection after
cellular infiltration and/or graft damage has occurred
[5], limiting a prognostic utility that may guide
optimization of immunosuppression therapy. Finally,
there is a noteworthy cost and patient inconvenience
associated with EMB surveillance. Consequently, a sig-
nificant interest in developing novel surveillance strat-
egies has fueled many attempts at finding alternative
non-invasive tests to monitor allograft status [6].
A number of alternative tests have been developed but
have either failed to deliver adequate performance or their
implementation proved complex [5]. In contrast, in a large
randomized controlled trial, a non-invasive gene expres-
sion profiling (GEP) test (AlloMap®, CareDx, Brisbane,
California) was found to be non-inferior to routine EMB
for surveillance after heart transplantation in selected low-
risk patients with respect to clinical outcomes [7]. The test
is performed on a peripheral blood sample; the results are
reported as a single GEP score (range from 0 to 40) [8].
Since the GEP test became available in 2005, more than
69,500 tests have been performed on more than 15,000
unique heart transplant recipients. This surveillance meth-
odology has been generally used in adult patients older
than 15 years for identification of heart transplant recipi-
ents at a low risk of acute cellular rejection at time of
testing [2].
In addition to the diagnostic utility of the single GEP
score, Deng and colleagues noted an association be-
tween low variability of serial GEP scores and the clin-
ical stability in patients [9]. These initial findings have
been independently confirmed by post-hoc multivariate
analyses of 602 heart transplant patients enrolled in the
Invasive Monitoring Attenuation by Gene Expression
Profiling (IMAGE) study [10]. This analysis suggested
that the variability of GEP scores from an individual
may predict the risk of future allograft dysfunction or
death in that individual. The prognostic utility of serial
GEP scores in predicting a clinical event was found to
be independent of, and complementary to, the original
use of a single GEP score in estimating the probability of
acute cellular rejection at the time of testing. However,
further validation of a serial characteristic of GEP scores
was suggested [10].
Therefore, in the current study, we expanded on the
earlier findings by conducting an analysis of an inde-
pendent patient population from the Cardiac Allograft
Rejection Gene Expression Observational (CARGO) II
study to determine: (1) the prognostic utility of within-
patient variability of GEP scores in predicting future sig-
nificant clinical events; (2) the negative predictive value
(NPV) and the positive predictive value (PPV) of GEP
score variability in predicting future significant clinical
events.
Methods
Ethics, consent and permissions
The CARGO II study was approved by local institutional
review boards or ethics committees of 12 participating
institutions (Instituto de Investigación Biomédica de A
Coruña (INIBIC), Complexo Hospitalario Universitario de
A Coruña (CHUAC), SERGAS. Universidade da Coruña,
Spain; University Hospital Muenster, Muenster, Germany;
Medical University of Vienna, Vienna, Austria; Hannover
Medical School, Hannover, Germany; Toronto General
Hospital, Toronto, Canada; Papworth Hospital, Papworth
Everard, Cambridge, United Kingdom; Silesian Center for
Heart Disease, Zabrze, Poland; Ospedali Riuniti di
Bergamo, Bergamo, Italy; Innsbruck Medical University,
Innsbruck, Austria; Groupe Hospitalier Pitié-Salpêtrière,
Paris, France; University Hospital of Leuven, Leuven,
Belgium; Deutsches Herzzentrum Berlin, Berlin,
Germany). The study was appropriately registered (clini-
caltrials.gov identifier NCT00761787) and was conducted
in accordance with the declaration of Helsinki and Good
Clinical Practices [4]. Patients were enrolled at any time
post-transplantation after giving a written informed con-
sent to the performance of EMB as part of routine care,
the collection of blood samples for research purposes
and the use of clinical data [10]. All authors had access
to the study data and reviewed and approved the final
manuscript.
Study design and patients
The CARGO II, a prospective observational multi-center
trial, was carried out at 17 academic centers (13 from
Europe and 4 from North America). Between May 2005
and February 2009, the study enrolled 737 new and
existing heart transplant patients who were ≥18 years
old and received post-transplant care at the participating
centers. Patients who were enrolled in a double blind
trial investigating immunosuppressive drugs were ex-
cluded from the study. During the study, data on clinical
status, EMB grades, echocardiography results and blood
for GEP testing were collected at routine surveillance
visits. After the last study visit, all participating centers
Crespo-Leiro et al. BMC Cardiovascular Disorders  (2015) 15:120 Page 2 of 9
were asked to collect further outcome data on all previ-
ously enrolled study subjects. This follow-up case report
form included information on the patient’s vital status
and causes of death (e.g. infection, malignancy, renal
failure or cardiac related), re-transplantation and events
of graft failure (see outcome measures).
For this report, we utilized a case cohort study design,
a powerful choice for follow-up studies of multiple event
types of interest, particularly in the field of human gen-
omics [11]. We selected samples from 12 centers that
provided clinical status and events data up to three years
following the last study visit.
Surveillance testing
The heart transplant recipients enrolled in the study
underwent long-term rejection surveillance, with or with-
out EMB. With regards to GEP testing, prepared, frozen
blood samples were shipped in standardized packages to
the Clinical Laboratory Improvement Amendments
(CLIA) certified laboratory (CareDx, Brisbane, California)
where the GEP testing was performed (Additional file 1).
The AlloMap test has been described in detail previously
[7]. Briefly, the test evaluates the expression level of 11 in-
formative genes and 9 genes used for control and
normalization [8]. The results are reported as a single
GEP score. The test score is associated with a NPV that
estimates the probability that a patient is not experiencing
≥2R acute cellular rejection [2]. For example, a GEP test
score of 32 is associated with a NPV of 98.0 % at 2–6
months post transplant and 99.0 % at more than 6 months
post-transplant.
Outcome measures and study groups
The composite primary clinical outcome of this study
was an event of death from any cause, re-transplantation
or graft failure. Graft failure was defined as a clinically
significant hemodynamic compromise (left ventricular
ejection fraction ≤40 %, use of hemodynamic support
such as inotropic medications and/or mechanical assist
device, hospitalization for treatment of graft failure or
dysfunction).
The event cohort consisted of all patients who had an
event ≥315 days post-transplant. Previous studies have re-
ported that a mean of 3.5 [10] or 4.4 [12] tests/patient
have been performed within a 2 years span. Therefore, for
the composite event group we included patients who had
at least four GEP serial scores prior to the first event. For
the control group, we required patients to have at least
four serial GEP scores and remain free of an event, before
the end of the observation span of study. We also included
only the GEP scores that were collected ≥315 days post-
transplantation, because of the known upward drift of the
mean GEP scores in the first 2 to ~12 months post-
transplantation [12]. In an analysis of the population of
heart transplant recipients receiving commercial GEP sur-
veillance testing (32,043 GEP tests from 9272 patients),
the mean GEP scores increased from an average of 21 at
two months to 29 at ~12 months post-transplant. In the
next few years beyond ~12 months, the population’s mean
GEP score remained stable [12]. Furthermore, we included
all clinical events from all patients who had the required 4
serial GEP scores. The time interval between the first and
the fourth GEP test visits was at least 85 days apart and at
most 780 days apart (Fig. 1).
Of the 737 patients enrolled in the CARGO II study,
333 were excluded (236 from 5 centers not providing
follow-up events data and 97 with only one GEP score).
Of the 404 remaining patients with longitudinal GEP
scores and at least a 3 year follow-up, 288 patients did
not have events and were suitable to be controls, but as
these were in abundance, we randomly chose 55 patients
to be controls and excluded 233. The final cohort of 91
patients thus included all 36 patients who experienced at
least one of the predefined clinical events and were in-
cluded in the event group and 55 patients without
events serving as the control group (Fig. 2). The control
patients were balanced to the event group with respect
to the number of study visits.
GEP score variability (AlloMap score variability, AMV)
was defined as the standard deviation of the four consecu-
tive scores collected ≥315 days post-transplantation. For
this calculation, the individual scores used were the direct
Fig. 1 Timing of four serial gene expression profiling scores to predict future clinical events. Four gene expression profiling (GEP) scores were
collected beginning day 315 post-transplant. The first and the fourth GEP score were at least 85 days apart and at most 780 days apart. Clinical
events were observed≥ 3 years after the last available score (GEP 4). Therefore, the overall follow-up was up to 6 years (if the patient enrolled in
the beginning of 2006 and had a clinical follow-up in late 2011). DOT: date of transplant
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output of the GEP linear discriminate algorithm (LDA)
prior to the step that transforms the LDA score to the
non-linear GEP score that fits within the 0–40 scale used
for the AlloMap report (Additional file 2). The detailed
computations of the GEP score variability are presented in
Additional file 3.
Statistical methods
All statistical analyses were performed using R software©,
2015, version 3.2.0 (The R Foundation for Statistical
Computing, Vienna, Austria), according to the study-
group assignment. The area under the receiver operating
characteristics curve (AUC ROC) was used to evaluate the
prognostic utility of GEP score variability in discriminat-
ing between low- and high-risk patients with respect to
the occurrence of future events. Sensitivity and specificity
were determined for all GEP score variability values be-
tween 0.1 and 2.1. Using observed event rates from the
CARGO II study, estimates and confidence intervals for
PPV and NPV were computed. Confidence intervals (CI)
for sensitivity and specificity were calculated using the
Clopper-Pearson exact method. Confidence intervals for
AUC ROC, NPV and PPV were calculated using re-
sampling methods. Demographic variables were compared
using the two-sample t-test (age) and two-tailed Fisher’s
exact test (categorical variables). The comparisons of days
between visits were done using the Wilcoxon test and
were reported in terms of medians and inter-quartile
range (IQR).
Results
Patients
The baseline characteristics of patients were well matched
between the two study groups (Table 1). The median
number of days from the fourth test to an event was 391
(IQR 376) days.
In the event group, the median interval between
transplant and the first GEP test eligible for the GEP
variability computation was 1298 (IQR 1975) days; in the
control group the median interval was 794 (IQR 1147)
Fig. 2 Creation of study cohort using the Cardiac Allograft Rejection Gene Expression Observational (CARGO) II study database. Of 737 patients
enrolled in CARGO II study, 171 had at least two gene-expression profiling (GEP) scores and three year follow-up data available. For our cohort,
we finally selected 91 patients with at least four serial gene expression profiling scores. These patients were assigned to either an event group or
a control group
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days, P = 0.351. In the event group and the control group,
the last test was performed at a median of 1489 (IQR
2005) and 1119 (IQR 1262) days post-transplant respect-
ively, P = 0.399. There was no statistical difference be-
tween the groups in number of days between the first and
the last GEP test; in the event group, the median was
336 days (IQR 147) and in the control group, the median
was 315 (IQR 108) days, P = 0.858.
GEP score variability
Of all patients, 63 % (57/91) had a GEP score variability
≤1.0; 16 % (15/91) of patients had a score variability
≤0.5. The majority of patients had GEP score variability
ranging from 0.5 to 1.5 (78 %, 71/91). The distribution
of the GEP scores in both study groups is shown in
Fig. 3.
The estimated prevalence of events in our data set was
17 %. The AUC ROC for the GEP score variability to
predict a composite, clinically significant event was 0.72,
95 % CI from 0.61 to 0.81 (Fig. 4).
The GEP score variability NPV and PPV performance
characteristics are shown in Table 2. In our study, the
NPV increased from 87.4 % (95 % CI 80.1-92.9) at a
GEP score variability of 1.0 to 97 % (95 % CI 91.4-100.0)
at a GEP score variability of 0.6. The PPVs for the same
score decreased from 26 % (95 % CI 14.8-41.8) at a GEP
score variability of 1.0 to 23.3 % (95 % CI 15.7-33.0) for
a GEP score variability of 0.6. For a GEP score variability
cutoff of 1.5, the estimated PPV is 35.4 % (95 % CI 13.5-
75.8).
In the event group 58 % (21/36) of patients died, 31 %
(11/36) experienced graft failure and 11 % (4/36) under-
went cardiac re-transplantation.
Discussion
The most important finding of this study is that the GEP
score variability may be useful in estimating the probabil-
ity of future events of death, re-transplantation or graft
failure in heart transplant recipients undergoing surveil-
lance with GEP testing ≥315 days post-transplantation. A
low variability of sequential GEP scores (≤0.6), which was
found in 24.2 % of the study population, rendered NPVs
of ≥97.0 % (Table 2), indicating clinical utility of GEP
score variability in the identification of patients at a low
risk for future clinical events of greatest concern. This
finding may have important clinical implications in the
longer-term management of heart transplant recipients as
the low risk patients may be good candidates for
optimization (i.e. reduction) of their immunosuppressive
drugs. Consequently, we speculate that this may reduce
the rate of unwanted adverse effects associated with
chronic immunosuppression, particularly infections and
nephrotoxicity. We believe that future GEP studies should
focus on personalization of long-term immunosuppressive
therapy and potential improvements in long-term out-
comes of heart transplant recipients.
Using peripheral-blood specimens, the AlloMap gene
expression test translates the complex gene expression
patterns of the mononuclear blood cells into a single
score (0–40) using a proprietary algorithm (Additional
file 2). The risk of rejection is considered to be higher
immediately after transplantation and lower by six to
12 months post-transplant [13]. In the IMAGE study,
the use of a single gene expression profiling score (below
the 34 threshold) to assess a risk of acute cellular rejec-
tion in clinically stable patients six months post cardiac
transplant resulted in a significant decrease in the num-
ber of EMB performed. This reduction was achieved
without adversely affecting patient outcomes [7]. More
recently, another randomized clinical trial has shown
similar results in patients who began the AlloMap surveil-
lance two months post-transplant, which is considered a
higher risk rejection time frame [14]. Primarily based on
the IMAGE study results, the International Society of
Table 1 Baseline characteristics of study patients
Characteristics Event group
(n = 36)
Control group
(n = 55)
P values
Age , years, mean
(standard deviation)a
53.5 (13.8) 54.4 (13.1) 0.759
Male sex, n (%) 29 (81) 46 (84) 0.781
Race, n (%)
Caucasian 34 (94) 54 (98) 0.560
Other 2 (6) 1 (2) 0.560
Indication for cardiac
transplantation, n (%)
Coronary Artery Disease 15 (42) 18 (33) 0.504
Idiopathic Cardiomyopathy 14 (39) 30 (55) 0.198
Valvular Heart Disease 2 (6) 3 (5) 1.000
Acute Myocarditis 1 (3) 2 (4) 1.000
Congenital Heart Disease 1 (3) 0 (0) 0.396
Other indications 3 (8) 3 (4) 0.381
Use of ventricular assist device
before transplantation, n (%)
6 (17) 13 (24) 0.599
Induction therapy (any), n (%) 28 (79) 45 (82) 0.784
Cytomegalovirus serology (IgG)
status, n (%)
Donor and Recipient Positive 13 (36) 13 (24) 0.239
Donor and Recipient Negative 7 (19) 9 (16) 0.781
Donor Positive and Recipient
Negative
3 (8) 6 (11) 1.000
Donor Negative and
Recipient Positive
6 (17) 14 (25) 0.439
Unknown 7 (19) 13 (24) 0.797
P values were calculated using two-tailed Fisher’s exact test unless
indicated otherwise
aTwo-sample t-test
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Heart and Lung Transplantation (ISHLT) suggested that a
single AlloMap score can be used to rule out the presence
of acute cellular rejection of ≥ 2R in selected low-risk pa-
tients [2]. In contrast, the GEP score variability analysis
was performed to aid clinicians in assessing the future risk
of a significant clinical event (death, re-transplantation or
graft failure). In the field of transplant cardiology, there is a
paucity of biomarkers that can reliably predict which
patients are at risk of adverse clinical events [15]. There is
a growing need to develop evidence-based personalized
strategies to optimize immunosuppressive therapy, im-
prove long-term outcomes and reduce complications [15].
Therefore, and in addition to the individual GEP score
and clinical assessment, the GEP score variability may
provide useful complementary information that may help
personalize long-term care of heart transplant recipients.
Deng and colleagues computed GEP score variability
and performed post-hoc analyses on IMAGE patients
who had at least two single GEP scores before an event
or study end [10]. In that study, multivariate analyses re-
vealed that only GEP score variability was significantly
associated with future clinical events; gender, race, age
and cytomegalovirus serological status were not. In the
Fig. 3 Distribution of gene expression profiling scores of all study patients assigned to the event group and the control group
Fig. 4 The area under the receiving operator characteristics (AUC
ROC) for AlloMap score variability to predict future clinical events
(death from any cause, re-transplantation or graft failure)
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cohorts presented in this article, we prospectively ana-
lyzed clinical outcome data of the CARGO II patients
who had four GEP scores preceding a first clinical event
(event group) or had 4 sequential GEP scores without a
subsequent event (control group). In addition to the fact
that a mean of 3.5 or 4.4 tests are performed within a
two year surveillance interval [10, 12], our decision to
use four serial GEP scores was based on calculating 85 %
probability of being within twofold of true variance
(using 3 scores yields 76 % probability). Although we in-
cluded two more GEP scores than Deng and colleagues
in our calculation, the formula for computing GEP score
variability remained the same (Additional file 3) [10].
Importantly, enrollment in the current study began in
2005. The latest follow-up clinical data was provided by
the end of 2011, allowing us to predict a significant clin-
ical event up to 6 years following heart transplantation.
Finally, we also computed NPV, PPV, sensitivity and spe-
cificity for the range of GEP score variability between 0.1
and 2.1.
Our results must be interpreted while considering the
limitations of this study. First, our composite primary clin-
ical outcome is a mixture of clinical conditions including
subtypes of events that were rare (e.g. only four events of
re-transplantation). In the future, we would aim to
collect larger numbers and/or more specific subtypes of
endpoints with sufficient power to be separately ana-
lyzed (e.g. deaths from infections or cancers due to
long term sequelae of over-immunosuppression). Add-
itionally, the expression levels of the informative genes
used to compute GEP scores in some cases may reflect
a feature of the status of the recipient’s immune system
that is not directly associated with the allograft [10].
Previous studies have indicated that prednisone doses
above 20 mg/day may reduce the GEP score by inhibit-
ing the expression of IL1R2, FLT3, and ITGAM genes
[10]. Most recently, it has been reported that acute
cytomegalovirus infections may be associated with in-
creased GEP scores in the absence of acute cellular
rejection [16]. Our retrospective analysis of this case-
cohort study may introduce potential, unintentional
bias in the selection of patients. To minimize selection
bias, we included all patients who met our predeter-
mined definition of clinical events in the event group.
All other non-event patients from the CARGO II study
who had four GEP scores were assigned to the control
group. Moreover, one may argue that the limited sam-
ple size (36 in the event group and 55 in the control
Table 2 GEP variability performance results
Variability
Score
Scores≤
Threshold %
PPV % NPV % Sensitivity % Specificity %
(95 % CI) (95 % CI) (95 % CI) (95 % CI)
0.1 0.0 17.0 (−−) - 100.0 (90.3–100) 0.0 (0.0–6.5)
0.2 1.1 17.2 (11.6–23.8) 100.0 (−−) 100.0 (90.3–100) 1.8 (0.0–9.7)
0.3 3.3 17.8 (12.3–24.7) 100.0 (−−) 100.0 (90.3–100) 5.5 (1.1–15.1)
0.4 7.7 19.0 (13.1–26.9) 100.0 (−−) 100.0 (90.3–100) 12.7 (5.3–24.5)
0.5 16.5 22.0 (15.2–30.8) 100.0 (−−) 100.0 (90.3–100) 27.3 (16.1–41.0)
0.6 24.2 23.3 (15.7–33.0) 97.0 (91.4–100.0) 94.4 (81.3–99.3) 36.4 (23.8–50.4)
0.7 33.0 23.2 (15.4–33.7) 92.8 (85.4–97.8) 83.3 (67.2–93.6) 43.6 (30.3–57.7)
0.8 42.9 25.2 (16.3–37.1) 91.4 (84.2–96.5) 75.0 (57.8–87.9) 54.5 (40.6–68.0)
0.9 56.0 29.7 (18.5–46.0) 90.3 (83.9–95.2) 63.9 (46.2–79.2) 69.1 (55.2–80.9)
1.0 62.6 26.0 (14.8–41.8) 87.4 (80.1–92.9) 50.0 (32.9–67.1) 70.9 (57.1–82.4)
1.1 68.1 27.8 (15.3–46.5) 87.0 (80.4–92.4) 44.4 (27.9–61.9) 76.4 (63.0–86-8)
1.2 71.4 29.9 (16.3–51.0) 87.0 (80.3–92.2) 41.7 (25.5–59.2) 80.0 (67.0–89.6)
1.3 76.9 29.4 (14.6–53.4) 86.0 (79.3–91.3) 33.3 (18.6–51.0) 83.6 (71.2–92.2)
1.4 83.5 31.9 (13.5–63.2) 85.3 (78.7–90.6) 25.0 (12.1–42.2) 89.1 (77.8–95.9)
1.5 87.9 35.4 (13.5–75.8) 84.9 (78.5–90.1) 19.4 (8.2–36) 92.7 (82.4–98.0)
1.6 92.3 29.4 (5.9–100.0) 83.9 (77.1–89.4) 11.1 (3.1–26.1) 94.5 (84.9–98.9)
1.7 94.5 31.9 (0.0–100.0) 83.7 (77.1–89.1) 8.3 (1.8–22.5) 96.4 (87.5–99.6)
1.8 97.8 23.8 (−−) 83.2 (76.6–88.6) 2.8 (0.1–14.5) 98.2 (90.3–100.0)
1.9 98.9 100.0 (−−) 83.4 (77.0–88.7) 2.8 (0.1–14.5) 100.0 (93.5–100.0)
2.0 98.9 100.0 (−−) 83.4 (77.0–88.7) 2.8 (0.1–14.5) 100.0 (93.5–100.0)
2.1 100.0 — (−−) 83.0 (76.6–88.4) 0.0 (0.0–9.7) 100.0 (93.5–100.0)
CI confidence interval, GEP gene expression profiling, NPV negative predictive value, PPV positive predictive value
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group) and the imbalance between the number of pa-
tients in each study group could affect our findings.
The use of unequal assignments ≤ 3:1 between study
groups does not significantly reduce the power of the
study [17]. Also, the baseline characteristics of study
patients were well-matched at entry.
In our study, the performance of the GEP score
variability in predicting outcomes for patients who
were monitored with GEP testing ≥315 days post-
transplantation (AUC ROC of 0.72, 95 % CI 0.61 to
0.81) is similar to the performance of the established
single GEP score in ruling out acute cellular rejection
for patient samples ≥2-6 month post-transplant (AUC
ROC 0.71, 95 % CI 0.56 to 0.84). The limited PPV of
the GEP score variability (Table 2) will undoubtedly be
compared with interpretation of EMB findings for
acute cellular rejection of cardiac transplants. In an-
other report, observed agreement between local and
central pathologists for EMB scoring was 28 % for
grade ≥ 2R (2004 ISHLT grading system) [4]. Despite
the ISHLT simplification of the 1990 grading classifica-
tion, suboptimal EMB readings are still common [4].
Furthermore, the GEP score variability may predict fu-
ture clinical events rather than be used for ruling out
acute cellular rejection at the time of a test. In this
study, the estimated PPVs do not exceed 36 % for vari-
ability values of up to 1.7. This limitation of the PPV is
in part attributable not only to the underlying sensitiv-
ity of this measure, but to the low prevalence of events
in the study population. Since the NPV exceeds 97 %
for variability values of ≤0.6, this test result may be
best suited for use to “rule-out” rather than for use to
“rule in” the likelihood of a future clinical event
(Table 2). Specific NPV and PPV values (Table 2) are
provided to aid clinicians in estimating the likelihood
of death, re-transplantation and graft dysfunction oc-
curring in patients beyond 315 days post-transplant.
However, the clinician may choose how to use the par-
ticular GEP score variability threshold based on a prac-
tical experience and make an associated clinical
interpretation based on overall clinical presentation of
the individual patient. Based on the results of this study,
we suggest use of GEP score variability to predict a future
composite clinical event (death from any cause, re-
transplantation or graft failure) only for GEP tests col-
lected at ≥315 days post-transplant. For example, the pa-
tients with GEP score variability ≥1.6 (approximately 8 %
of the CARGO II population) may be at a higher risk of
experiencing an event (PPV ~30 %; Table 2). These pa-
tients may be candidates for more vigilant surveillance
and appropriately timely interventions. On the other hand,
patients with a low GEP score variability, particularly
scores ≤ 0.6 (approximately 25 % of our population) may
be at a low risk of experiencing a clinical event (NPV
≥97 %) and may be potential candidates, depending on the
full clinical circumstances in each case, for reduced
immunosuppression.
Conclusions
The GEP score variability may be used in estimating the
likelihood of events of death, re-transplantation or graft
dysfunction occurring in patients beyond 315 days post-
transplant and thus may aid physicians in identifying
heart transplant recipients who may need more or less
intensive further surveillance. Prospective studies of
GEP score variability including a larger number of pa-
tients and events from the Outcome AlloMap Registry
are desirable in the future.
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